BRAF-altered CRC highlights from ASCO GI 2025

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Dr Elena Élez provides her insights on the latest data on BRAF-altered colorectal cancer presented at the ASCO GI 2025 congress.

Watch and listen as Dr Élez provides her key takeaways that could impact clinical practice.

Key clinical takeaways:

- BREAKWATER: demonstrated a statistically significant and clinically meaningful benefit in ORR with EC + mFOLFOX6 that was rapid and durable in BRAF V600E-mutant mCRC. The results support EC + mFOLFOX6 as a new first-line SOC for patients with BRAF V600E-mutant CRC

- CHECKMATE 8HW:NIVO + IPI demonstrated statistically significant and clinically meaningful improvement in PFS vs NIVO in patients with MSI-H/dMMR mCRC across all lines of therapy and across prespecified subgroups, including patients who also harboured a BRAF mutation



Follow us on social media:

X: https://x.com/giconnectInfo

LinkedIn: https://www.linkedin.com/company/giconnect/

This content is intended for healthcare professionals outside the UK & ROI only.

The medical expert in this video is expressing her own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the expert.



This video is developed by cor2ed.com

Published February 2025



Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Category
Oncology
Be the first to comment

Up Next